Compare LESL & SER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LESL | SER |
|---|---|---|
| Founded | 1963 | 2017 |
| Country | United States | United States |
| Employees | N/A | 13 |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.7M | 19.4M |
| IPO Year | 2020 | N/A |
| Metric | LESL | SER |
|---|---|---|
| Price | $1.47 | $1.72 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | $2.54 | ★ $15.00 |
| AVG Volume (30 Days) | ★ 133.1K | 68.8K |
| Earning Date | 05-18-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,241,915,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.62 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.27 | $1.22 |
| 52 Week High | $6.92 | $7.92 |
| Indicator | LESL | SER |
|---|---|---|
| Relative Strength Index (RSI) | 46.89 | 38.22 |
| Support Level | $0.90 | $1.53 |
| Resistance Level | $1.60 | $1.86 |
| Average True Range (ATR) | 0.27 | 0.10 |
| MACD | -0.06 | -0.02 |
| Stochastic Oscillator | 12.38 | 2.48 |
Leslies Inc is a direct-to-consumer pool and spa care brand offering a comprehensive assortment of products, including chemicals, equipment and parts, cleaning and maintenance equipment, and safety, recreational, and fitness-related products. The company serves residential pool, residential spa, professional pool, and commercial pool consumers and markets its products through over 1,000 company-operated locations in 39 states and e-commerce websites, operating only in the United States. It operates mainly in the pool and spa aftermarket industry and offers regularly purchased, non-discretionary maintenance items, along with installation and repair services for pool and spa equipment.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.